For research use only. Not for therapeutic Use.
MK-4101 is an investigational drug developed by Merck, designed as a selective inhibitor of the Rho-associated coiled-coil containing protein kinase 2 (ROCK2). This drug is primarily studied for its potential therapeutic effects in treating autoimmune diseases, including rheumatoid arthritis (RA) and inflammatory conditions. By modulating the ROCK2 pathway, MK-4101 aims to reduce inflammation and immune cell activation, potentially offering a novel approach for managing chronic inflammatory diseases and improving patient outcomes.
| Catalog Number | I005555 |
| CAS Number | 935273-79-3 |
| Synonyms | MK4101;MK 4101 |
| Molecular Formula | C₂₄H₂₄F₅N₅O |
| Purity | ≥95% |
| Target | Hedgehog |
| Solubility | DMSO: 10 mM |
| Storage | Store at -20°C |
| InChI | InChI=1S/C24H24F5N5O/c1-34-17(15-4-2-3-5-16(15)24(27,28)29)31-32-20(34)22-9-6-21(7-10-22,8-11-22)19-30-18(35-33-19)14-12-23(25,26)13-14/h2-5,14H,6-13H2,1H3 |
| InChIKey | HKJOIWLYDJCTQR-UHFFFAOYSA-N |
| SMILES | CN1C(=NN=C1C23CCC(CC2)(CC3)C4=NOC(=N4)C5CC(C5)(F)F)C6=CC=CC=C6C(F)(F)F |
